MacroGenics Now Covered by Oppenheimer (MGNX)
Equities research analysts at Oppenheimer assumed coverage on shares of MacroGenics (NASDAQ:MGNX) in a research note issued to investors on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $48.00 price target on the stock. Oppenheimer’s price target would indicate a potential upside of 141.94% from the stock’s previous close.
Shares of MacroGenics (NASDAQ:MGNX) traded up 0.51% on Thursday, hitting $19.82. 349,965 shares of the company’s stock traded hands. MacroGenics has a 52 week low of $17.96 and a 52 week high of $41.00. The stock’s 50-day moving average is $20.92 and its 200-day moving average is $27.71. The company’s market cap is $547.4 million.
MacroGenics (NASDAQ:MGNX) last released its earnings data on Tuesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03. Analysts expect that MacroGenics will post $-1.01 EPS for the current fiscal year.
In other MacroGenics news, VP Eric Blasius Risser sold 8,000 shares of the company’s stock on the open market in a transaction dated Monday, June 30th. The shares were sold at an average price of $21.84, for a total value of $174,720.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of other firms have also recently commented on MGNX. Analysts at Roth Capital raised their price target on shares of MacroGenics from $28.00 to $30.00 in a research note on Thursday, June 19th. Five equities research analysts have rated the stock with a buy rating, MacroGenics currently has an average rating of “Buy” and a consensus target price of $50.50.
MacroGenics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.